Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years

BACKGROUND: Pneumococcal conjugate vaccines (PCVs) have significantly reduced pneumococcal disease, but disease from non-PCV serotypes remains. The safety, tolerability, and immunogenicity of a 20-valent PCV (PCV20) were evaluated. METHODS: This pivotal phase 3, randomized, double-blind study enroll...

Descripción completa

Detalles Bibliográficos
Autores principales: Essink, Brandon, Sabharwal, Charu, Cannon, Kevin, Frenck, Robert, Lal, Himal, Xu, Xia, Sundaraiyer, Vani, Peng, Yahong, Moyer, Lisa, Pride, Michael W, Scully, Ingrid L, Jansen, Kathrin U, Gruber, William C, Scott, Daniel A, Watson, Wendy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427137/
https://www.ncbi.nlm.nih.gov/pubmed/34940806
http://dx.doi.org/10.1093/cid/ciab990

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427137/
https://www.ncbi.nlm.nih.gov/pubmed/34940806
http://dx.doi.org/10.1093/cid/ciab990

Ejemplares similares